What Halozyme’s Q1 earnings mean for stock watchers

Halozyme Therapeutics (HALO) just put out a busy Q1 2026 update, combining strong year-over-year growth in revenue and earnings with reaffirmed full year guidance and a fresh US$1b share repurchase program.

The quarter was also active on the partnership side, with a new global collaboration around the ENHANZE drug delivery platform and oncology targets, giving investors more concrete data points to weigh against recent share price moves.

After a strong Q1 update and fresh GSK collaboration headlines, Halozyme’s recent momentum shows in a 5.55% 7 day share price return. However, the stock is still down 8.96% over 90 days, while the 1 year total shareholder return of 46.17% points to a much stronger longer term picture than the short term swings might suggest.

If this earnings story has you looking at other healthcare opportunities, it could be worth scanning for companies using AI in medicine through our 33 healthcare AI stocks

With Halozyme trading at US$70.03 against an average analyst target of about US$85, and management committing up to US$1b to buybacks, you have to ask: is this a genuine opening, or is future growth already priced in?

Most Popular Narrative: 18.4% Undervalued

Halozyme’s most followed valuation story pegs fair value at about $85.78 per share, which sits well above the latest close at $70.03. This puts the focus firmly on what needs to go right for that gap to close.

The accelerating adoption of subcutaneous drug delivery in place of traditional intravenous administration, evidenced by rapid conversion rates (e.g., DARZALEX subcutaneous now 96% in the US) and label expansions (Phesgo for at-home administration), positions Halozyme's ENHANZE platform as a core beneficiary of the global shift towards more patient-friendly, convenient, and cost-effective treatment modalities. This structural shift is expected to support continued robust growth in royalty revenues and net margin expansion over the long term.

Want to see what is behind that valuation gap? The narrative leans on compounding royalties, rising margins and a future earnings profile that assumes tighter share count.

Result: Fair Value of $85.78 (UNDERVALUED)

However, that upside story can be knocked off course if key royalty partners slow or lose exclusivity, or if ongoing patent challenges weaken ENHANZE’s long term edge.

Another Angle On Halozyme’s Valuation

The narrative points to Halozyme trading below an estimated fair value of about $85.78 per share, but the P/E ratio of 23.8x tells a tougher story. That is higher than the US Biotechs industry at 17.7x, the peer average at 22.1x, and the fair ratio of 17.8x. This suggests investors are already paying up and leaves less room if expectations slip even slightly. So is this a margin of safety or a premium that needs strong execution to hold up?

Next Steps

If this mix of optimism and caution feels balanced, consider acting while the information is fresh and weigh the company’s trade offs for yourself using its 3 key rewards and 4 important warning signs

Looking for more investment ideas?

If Halozyme has sharpened your focus, do not stop here. Use carefully filtered stock lists to quickly spot other opportunities that match your risk and return preferences.

• Zero in on potential value opportunities by reviewing companies flagged in the 47 high quality undervalued stocks.
• Prioritize resilience and capital strength with stocks highlighted in the solid balance sheet and fundamentals stocks screener (45 results).
• Get ahead of the crowd by scanning the screener containing 23 high quality undiscovered gems before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.